$0.49
17.13% yesterday
NYSE, May 20, 10:10 pm CET
ISIN
US9286611077
Symbol
VNRX
Sector

VolitionRX Stock price

$0.49
+0.01 2.72% 1M
-0.32 39.38% 6M
-0.11 18.17% YTD
-0.26 34.28% 1Y
-2.01 80.36% 3Y
-2.56 83.90% 5Y
-3.15 86.51% 10Y
NYSE, Closing price Tue, May 20 2025
+0.07 17.13%
ISIN
US9286611077
Symbol
VNRX
Sector

Key metrics

Market capitalization $50.58m
Enterprise Value $54.10m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 41.30
P/S ratio (TTM) P/S ratio 38.61
P/B ratio (TTM) P/B ratio negative
Revenue growth (TTM) Revenue growth 64.15%
Revenue (TTM) Revenue $1.31m
EBIT (operating result TTM) EBIT $-24.16m
Free Cash Flow (TTM) Free Cash Flow $-21.72m
Cash position $2.60m
EPS (TTM) EPS $-0.27
P/E forward negative
P/S forward 6.88
EV/Sales forward 7.36
Short interest 0.54%
Show more

Is VolitionRX a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,789 stocks worldwide.

VolitionRX Stock Analysis

Unlock Scores for Free

Analyst Opinions

5 Analysts have issued a VolitionRX forecast:

4x Buy
80%
1x Hold
20%

Analyst Opinions

5 Analysts have issued a VolitionRX forecast:

Buy
80%
Hold
20%

Financial data from VolitionRX

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
1.31 1.31
64% 64%
100%
- Direct Costs 1.29 1.29
8% 8%
98%
0.02 0.02
103% 103%
2%
- Selling and Administrative Expenses 12 12
24% 24%
885%
- Research and Development Expense 11 11
38% 38%
863%
-23 -23
33% 33%
-1,746%
- Depreciation and Amortization 1.29 1.29
8% 8%
98%
EBIT (Operating Income) EBIT -24 -24
32% 32%
-1,844%
Net Profit -24 -24
31% 31%
-1,834%

In millions USD.

Don't miss a Thing! We will send you all news about VolitionRX directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

VolitionRX Stock News

Neutral
PRNewsWire
one day ago
Clinical Paper Published in BMC Veterinary Research HENDERSON, Nev. , May 19, 2025 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, today announces the publication of "Evaluation of plasma nucleosome concentrations and the effect of pre-analytical variables in healthy cats" in BMC Veterinary Research.
Neutral
Seeking Alpha
4 days ago
VolitionRX Limited (NYSE:VNRX ) Q1 2025 Earnings Conference Call May 16, 2025 8:30 AM ET Company Participants Louise Batchelor – Chief Marketing and Communications Officer Terig Hughes – Chief Financial Officer Cameron Reynolds – Chief Executive Officer Conference Call Participants Steven Ralston – Zacks Ilya Zubkov – Freedom Broker Operator Good morning, ladies and gentlemen. Thank you for sta...
Neutral
PRNewsWire
5 days ago
Conference call to discuss financial and operational results scheduled for Friday, May 16 at 8:30 a.m. U.S. Eastern Time HENDERSON, Nev.
More VolitionRX News

Company Profile

VolitionRX Ltd. engages in the development of blood-based cancer tests to help diagnose a range of cancers. Its products include the Nucleosomics platform that identifies and measures nucleosomes in the bloodstream or other bodily fluids. The company was founded on September 24, 1998 and is headquartered in Henderson, NV.

Head office United States
CEO Cameron Reynolds
Employees 85
Founded 1998
Website www.volition.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today